Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000704877 | SCV000833849 | uncertain significance | Glycogen storage disease type III | 2022-07-25 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 984 of the AGL protein (p.Val984Ile). This variant is present in population databases (no rsID available, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with AGL-related conditions. ClinVar contains an entry for this variant (Variation ID: 581137). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV005328365 | SCV005996561 | uncertain significance | Inborn genetic diseases | 2025-01-26 | criteria provided, single submitter | clinical testing | The c.2950G>A (p.V984I) alteration is located in exon 23 (coding exon 22) of the AGL gene. This alteration results from a G to A substitution at nucleotide position 2950, causing the valine (V) at amino acid position 984 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000704877 | SCV002094514 | uncertain significance | Glycogen storage disease type III | 2020-09-22 | no assertion criteria provided | clinical testing |